Warren Buffett's Berkshire Hathaway (NYSE:BRK.B) just disclosed in a fourth-quarter filing that it has liquidated its position in big pharma stock GlaxoSmithKline (NYSE:GSK). Does that mean Buffett is abandoning the health-care industry? Should investors follow the Oracle of Omaha's lead and dump their pharma and biotech holdings?

In one word: No!

Taking a closer look at the 13F filing reveals Berkshire has not abandoned the industry. It still has a $30 million position in Johnson & Johnson, and $210 million stake in Sanofi, and is the largest single shareholder of DaVita. Buffett aggressively accumulated shares in the dialysis service provider last year, which are currently valued at $2.3 billion.

In this segment of The Motley Fool's health care-focused investing show Market Checkup, analyst David Williamson discusses what Buffett's decision to dump Glaxo means, dives in to the remaining health care holdings in Berkshire's portfolio, and highlights different strategies investors can take to profit from Warren Buffett's investing acumen.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.